News - Page 34 of 35 - MaRS Innovation

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions. “From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ... Read more

York University becomes 17th Member of MaRS Innovation

MaRS Innovation to act as commercialization agent for York's life sciences and technology discoveries, leveraging new potential for York's existing $70 million in research initiatives TORONTO, May 9, 2011 – York University has become the latest member of MaRS Innovation, the commercialization agent for many leading Toronto-based universities, hospitals and research institutes. “York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a ... Read more

OtoSim Inc. launches revolutionary simulator-training system to improve otoscopic diagnostic efficiency

MaRS Innovation provided crucial commercialization funding to support research from The Hospital for Sick Children MaRS Innovation (MI) and The Hospital for Sick Children (SickKids) have launched OtoSim Inc. to commercialize an otoscopy training system and process developed by two otolaryngologists at SickKids. The new product, the OtoSim™ program and training device, is the first in a series of training systems directed at improving the accuracy of ear examinations. Using simulation-based training is part of a wider trend in medicine. In otoscopy, healthcare professionals ... Read more

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it - part of a growing trend of selling science to help shore up Canada's troubled health-care system. Tuesday's agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question. But the licensing deal with one of the world's biggest drug companies ... Read more

MaRS Innovation brokers deal between sanofi-aventis and Sunnybrook Health Sciences Centre

Bridgewater, NJ and Toronto, ON- February 15, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers. “Our new relationship with Sunnybrook Health Sciences Centre fits our strategy ... Read more

MaRS Innovation welcomes Thunder Bay Regional Research Institute as newest member

Dr. John Rowlands’ X-ray Light Valve technology among the first TBRRI patents that MaRS Innovation will bring to market January 26, 2011 (Thunder Bay, ON) – Today, MaRS Innovation welcomes Thunder Bay Regional Research Institute (TBRRI) as its newest member. MaRS Innovation is an incorporated non-profit organization with an international, independent, industry-led Board of Directors. It is the commercialization agent for 16 member institutions that are leading Ontario life sciences and commercialization agents. Partners include the University of Toronto, Sunnybrook Health Sciences Centre, ... Read more

VitalHub featured on CBC’s Metro Morning

Matt Galloway, host of CBC's Metro Morning, spoke to Prateek Dwivedi, vice-president and chief information officer at Mount Sinai Hospital, about VitalHub's technology. Dwivedi's interview with Galloway is no longer publicly available. Dwivedi and Galloway touch on various product highlights, including: Longitudinal view of a patient's history and benefits of having access to that information when making rounds or walking between locations. Security concerns, including encryption, that are equivalent to those used in the hospital. Feedback from doctors, nurses and others who have used the product. MaRS ... Read more

How VitalHub Corp. Uses iPhones® To Help Health Care

TORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp.. The unique start-up company was spun-off from mobile health technologies developed  Toronto's Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector. MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto's ... Read more

$15M Funding announcement for CCRM

As part of MaRS Innovation's strategy to bundle technologies, our first initiative focused on regenerative medicine and creating the Centre for Commercialization of Regenerative Medicine (CCRM) located in Toronto, Ontario. We are pleased that these efforts have been recognized by the Government of Canada's National Centres of Excellence (NCE) program, which recently announced a $15 million funding grant for CCRM through the Centres of Excellence for Commercialization and Research. (more…) Read more

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread. Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy
 and
 GlaxoSmithKline
 chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 ... Read more
Page 34 of 35« First...1020...3132333435